Jiangxi Biopharmaceutical Ends HKD 10.4B IPO Subscription on June 25, Achieves 219x Oversubscription

According to market sources, Hong Kong-listed biotech company Jiangxi Biopharmaceutical (06915) completed its IPO subscription on June 25, 2026, securing HKD 10.4 billion in margin financing with 219-fold oversubscription based on public offering of HKD 47.32 million. The company plans to raise up to HKD 470 million, offering 36.2345 million H-shares priced between HKD 9.33 and HKD 13.06 per share. Trading is scheduled for June 30. Jiangxi Biopharmaceutical is China's largest human tetanus antitoxin provider, holding 65.8% domestic and 36.6% global market share by 2024 sales volume.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments